Full Text
The Full Text of this article is available as a PDF (215.8 KB).
Figure 1 .
American College of Rheumatology 20% response (ACR20) after treatment with anakinra administered as monotherapy, compared with placebo, in patients with rheumatoid arthritis. The early onset of action is demonstrated.
Figure 2 .
Magnitude of the American College of Rheumatology clinical responses after treatment with anakinra administered in combination with methotrexate in patients with rheumatoid arthritis (*p<0.05 v placebo).
Figure 3 .
Improvements in individual American College of Rheumatology criteria components after treatment with anakinra administered in combination with methotrexate. Patient centred outcomes are included in panel A; physician centred outcomes are included in panel B (*p<0.05; **p<0.01; ***p<0.001 v placebo).
Figure 4 .
Improvements in the Health Assessment Questionnaire (HAQ) disease index from the three efficacy studies of anakinra. Clinically relevant improvements (>-0.22) were observed in all.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bresnihan B., Alvaro-Gracia J. M., Cobby M., Doherty M., Domljan Z., Emery P., Nuki G., Pavelka K., Rau R., Rozman B. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998 Dec;41(12):2196–2204. doi: 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
- Cohen Stanley, Hurd Eric, Cush John, Schiff Michael, Weinblatt Michael E., Moreland Larry W., Kremer Joel, Bear Moraye B., Rich William J., McCabe Dorothy. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Mar;46(3):614–624. doi: 10.1002/art.10141. [DOI] [PubMed] [Google Scholar]
- Dayer J. M., Feige U., Edwards C. K., 3rd, Burger D. Anti-interleukin-1 therapy in rheumatic diseases. Curr Opin Rheumatol. 2001 May;13(3):170–176. doi: 10.1097/00002281-200105000-00004. [DOI] [PubMed] [Google Scholar]
- Dinarello C. A. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med. 2000 Sep 7;343(10):732–734. doi: 10.1056/NEJM200009073431011. [DOI] [PubMed] [Google Scholar]
- Felson D. T., Anderson J. J., Boers M., Bombardier C., Chernoff M., Fried B., Furst D., Goldsmith C., Kieszak S., Lightfoot R. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993 Jun;36(6):729–740. doi: 10.1002/art.1780360601. [DOI] [PubMed] [Google Scholar]
- Fries J. F., Spitz P., Kraines R. G., Holman H. R. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980 Feb;23(2):137–145. doi: 10.1002/art.1780230202. [DOI] [PubMed] [Google Scholar]
- Jiang Y., Genant H. K., Watt I., Cobby M., Bresnihan B., Aitchison R., McCabe D. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 2000 May;43(5):1001–1009. doi: 10.1002/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]